Lung cancer study: which targeted drug works best for rare mutation?
NCT ID NCT07458919
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two types of targeted therapy (first-generation vs third-generation EGFR TKIs) for people with advanced lung cancer that has a specific rare mutation called EGFR exon 19 deletion-insertion. About 94 participants will be randomly assigned to one of the two treatments to see which one helps them live longer without the cancer growing. The goal is to find the best first treatment for this group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR EXON 19 DELETION-INSERTION MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can a new PET tracer light up hidden cancers?
- Fellow veterans may hold the key to earlier lung cancer detection